← Back to Search

Unknown

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Phase 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 26 weeks

Summary

This trial is testing a new drug called BMS-986278 to help people with lung fibrosis. The goal is to see if it can reduce lung scarring and improve breathing. The study will also check if the drug is safe and how much of it stays in the body.

Eligible Conditions
  • Pulmonary Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 26 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 26 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS interval
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval
+1 more

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: PF-ILD Dose 2 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention
Group II: PF-ILD Dose 1 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention
PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
Group III: IPF Dose 2 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention
Group IV: IPF Dose 1 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention
IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
Group V: PF-ILD Placebo + Post Treatment Follow-up or OTEPlacebo Group1 Intervention
Group VI: IPF Placebo + Post Treatment Follow-up or OTEPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986278
2023
Completed Phase 2
~750

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,691 Previous Clinical Trials
4,097,189 Total Patients Enrolled
6 Trials studying Pulmonary Fibrosis
2,738 Patients Enrolled for Pulmonary Fibrosis
~75 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top